REG - Alliance Pharma PLC - AGM Statement

Alliance PharmaAnnouncement

18/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220518:nRSR8507La&default-theme=true

RNS Number : 8507L  Alliance Pharma PLC  18 May 2022

 

 For immediate release  18 May 2022

 

 

 

ALLIANCE PHARMA

("Alliance" or the "Group")

 

AGM statement

 

Alliance Pharma plc (AIM: APH), the international healthcare group, will hold
its Annual General Meeting ("AGM") at 10:00am this morning. At the meeting,
the Group's Chair, David Cook, will make the following statement:

 

"Firstly, on behalf of the Alliance Board, I would like to take this
opportunity to thank Alliance's employees around the world for their continued
commitment and support.

 

"The overall business is in good health and consumer demand for our brands
remains strong. The integration of ScarAway and the rights to Kelo-cote in the
US (acquired in March 2022) is progressing well.

 

"In line with the comments made at the FY 2021 results in March 2022, we
continue to expect FY 2022 performance to be weighted to H2 due to our
anticipated sales trajectory for Amberen and Nizoral, together with temporary
disruption to our supply chain through COVID-related lockdowns in China, which
is now beginning to ease.

 

"We remain confident in our ability to deliver full year financial performance
in line with market expectations. Further commentary on our first half trading
performance will be provided in our trading update in July 2022."

 

 

For further information:

 

 Alliance Pharma plc                                                       + 44 (0)1249 466966
 Cora McCallum, Head of Investor Relations & Corporate Communications      + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                  + 44 (0)20 7466 5000
 Mark Court / Sophie Wills / Hannah Ratcliff
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Numis Securities Limited                                                  + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith
 Corporate Broking: James Black

 Investec Bank plc                                                         + 44 (0)20 7597 5970
 Corporate Finance: Daniel Adams
 Corporate Broking: Patrick Robb

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our
purpose is to improve the lives of consumers and patients through making
available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented
by a smaller Prescription Medicines business. In total, we hold marketing
rights to around 80 brands, with revenues generated from a mix of direct,
distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics operations, we remain asset-light
and focused on maximising the value of our brands.

For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMBKOBNOBKDKPD